PT - JOURNAL ARTICLE AU - Popkin-Hall, Zachary R. AU - Niaré, Karamoko AU - Crudale, Rebecca AU - Simkin, Alfred AU - Fola, Abebe A. AU - Sanchez, Juan F. AU - Pannebaker, Danielle L. AU - Giesbrecht, David J. AU - Kim, Isaac E. AU - Aydemir, Özkan AU - Bailey, Jeffrey A. AU - Valdivia, Hugo O. AU - Juliano, Jonathan J. TI - High-Throughput Genotyping of <em>Plasmodium vivax</em> in the Peruvian Amazon via Molecular Inversion Probes AID - 10.1101/2024.06.27.24309599 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.27.24309599 4099 - http://medrxiv.org/content/early/2024/06/28/2024.06.27.24309599.short 4100 - http://medrxiv.org/content/early/2024/06/28/2024.06.27.24309599.full AB - Plasmodium vivax transmission occurs throughout the tropics and is an emerging threat in areas of Plasmodium falciparum decline, causing relapse infections that complicate treatment and control. Targeted sequencing for P. falciparum has been widely deployed to detect population structure and the geographic spread of antimalarial and diagnostic resistance. However, there are fewer such tools for P. vivax. Leveraging global variation data, we designed four molecular inversion probe (MIP) genotyping panels targeting geographically differentiating SNPs, neutral SNPs, putative antimalarial resistance genes, and vaccine candidate genes. We deployed these MIP panels on 866 infections from the Peruvian Amazon and identified transmission networks with clonality (IBD&gt;0.99), copy number variation in Pvdbp and multiple Pvrbps, fixation of putative antimalarial resistance, and balancing selection in 13 vaccine candidate genes. Our MIP panels are the broadest genotyping panel currently available and are poised for successful deployment in other regions of P. vivax transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute for Allergy and Infectious Diseases (R01AI165537, K24AI134990, and R01TW010870 to JJJ) and by the Armed Forces Health Surveillance Division (AFHSD), Global Emerging Infections Surveillance (GEIS) Branch, ProMIS ID P0091_24_N6.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for this study was approved by the Institutional Review Board of the U.S Naval Medical Research Unit SOUTH (NAMRU SOUTH) in compliance with all applicable federal regulations governing the protection of human subjects (protocol NMRCD.2007.0004). Informed consent was obtained from all participants. For participants aged 8 to 17 years, written consent from parents or guardians and assent from participants were obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesParasite sequence data is available through SRA (BioProject ID PRJNA1117913).